We are live on
!
Find out more
MP
Mangrove Partners Portfolio holdings
AUM
$1.24B
1-Year Est. Return
41.74%
This Fund
S&P 500
This Quarter
Est. Return
+32.76%
1 Year Est. Return
+41.74%
3 Year Est. Return
+169.22%
5 Year Est. Return
+150.23%
10 Year Est. Return
+417.9%
AUM
$410M
AUM Growth
-$315M
(-43%)
Cap. Flow
-$416M
Cap. Flow
% of AUM
-101.51%
Top 10 Holdings %
Top 10 Hldgs %
55.38%
Holding
93
New
16
Increased
4
Reduced
29
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PennyMac Financial
PFSI
|
+$8.75M |
| 2 |
KBR
KBR
|
+$8.75M |
| 3 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$7.63M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$7.55M |
| 5 |
Quanta Services
PWR
|
+$5.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$224M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$26.3M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$24.1M |
| 4 |
PDCE
PDC Energy, Inc.
PDCE
|
+$18.6M |
| 5 |
International Seaways
INSW
|
+$18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.23% |
| 2 | Financials | 14.43% |
| 3 | Industrials | 12.86% |
| 4 | Materials | 10.92% |
| 5 | Energy | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CIVI
1
DELISTED
Civitas Resources
CIVI
| $30.5M | 7.45% |
2,060,700
| – | – |
|
|
ECHO
2
EchoStar
ECHO
$25.5B
| $30.2M | 7.38% |
1,081,749
-569,334
| -34% | -$17.3M |
|
|
AAMI
3
Acadian Asset Management
AAMI
$2.88B
| $28.1M | 6.86% |
2,257,173
-1,983,946
| -47% | -$16.2M |
|
4
Super Micro Computer
SMCI
$19.5B
| $26.5M | 6.46% |
9,326,450
-3,943,410
| -30% | -$9.93M |
|
5
Green Plains
GPRE
$1.19B
| $26M | 6.33% |
2,541,050
-972,689
| -28% | -$7.17M |
|
6
PG&E
PCG
$47.8B
| $23.2M | 5.67% |
2,617,744
-1,026,842
| -28% | -$11.2M |
|
7
Cartesian Therapeutics
RNAC
$232M
| $18.6M | 4.54% |
218,226
+33,264
| +18% | +$3.02M |
|
8
SunCoke Energy
SXC
$757M
| $15.2M | 3.7% |
5,123,075
-668,417
| -12% | -$2.13M |
|
|
CPRX
9
DELISTED
Catalyst Pharmaceutical
CPRX
| $14.5M | 3.53% |
3,130,195
-1,225,221
| -28% | -$5.51M |
|
|
BMY.RT
10
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $14.1M | 3.45% |
3,946,145
+2,115,545
| +116% | +$7.63M |
|
|
CAI
11
DELISTED
CAI International, Inc.
CAI
| $14.1M | 3.44% |
845,512
-151,385
| -15% | -$2.52M |
|
12
TG Therapeutics
TGTX
$8.58B
| $13.4M | 3.27% |
688,224
-553,482
| -45% | -$8.91M |
|
|
13
PennyMac Financial
PFSI
$4.38B
| $11.5M | 2.82% |
+276,240
| New | +$8.75M |
|
|
EIGR
14
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $9.1M | 2.22% |
31,595
+8,801
| +39% | +$2.59M |
|
|
15
KBR
KBR
$4.68B
| $9.08M | 2.22% |
+402,499
| New | +$8.75M |
|
|
PDCE
16
CALL
DELISTED
PDC Energy, Inc.
PDCE
| $8.71M | 2.13% |
700,000
| – | – |
|
17
Genco Shipping & Trading
GNK
$1.17B
| $8.59M | 2.1% |
1,367,084
-212,238
| -13% | -$1.23M |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $8.29M | 2.02% |
144,115
-442,408
| -75% | -$24.1M |
|
|
BLUE
19
DELISTED
bluebird bio
BLUE
| $7.91M | 1.93% |
+10,007
| New | +$7.55M |
|
|
STON
20
DELISTED
StoneMor Inc.
STON
| $7.22M | 1.76% |
9,287,513
-423,501
| -4% | -$292K |
|
|
DSSI
21
DELISTED
Diamond S Shipping Inc. Common Shares
DSSI
| $6.68M | 1.63% |
835,910
-740,738
| -47% | -$7.82M |
|
22
Ameriprise Financial
AMP
$46.8B
| $6.5M | 1.59% |
+43,301
| New | +$5.55M |
|
|
23
Quanta Services
PWR
$93.9B
| $6.43M | 1.57% |
+163,918
| New | +$5.85M |
|
24
LPL Financial
LPLA
$26.3B
| $6.02M | 1.47% |
+76,804
| New | +$5.13M |
|
|
FLY
25
DELISTED
Fly Leasing Limited
FLY
| $5.83M | 1.42% |
710,380
-108,818
| -13% | -$758K |
|
Similar funds
GX
HCA
CA
WTA
NHAS
FLII
CCA
IC
Mangrove Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Mangrove Partners held 93 positions worth $410M, down 43% from $725M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Mangrove Partners withdrew a net $416M in Q2 2020, closing 41 positions and reducing 29 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $224M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 17% a quarter earlier, followed by Financials and Industrials.
Against the trend, Mangrove Partners opened a new position in PennyMac Financial worth $11.5M.
- Mangrove Partners's largest Q2 2020 buy was PennyMac Financial: 276,240 shares worth $11.5M.
- Mangrove Partners added most to Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020, an estimated $7.63M increase.
- Mangrove Partners's biggest Q2 2020 reduction was Iovance Biotherapeutics, cutting an estimated $26.3M.
- Mangrove Partners fully exited iShares Russell 2000 ETF in Q2 2020, selling an estimated $224M.
- Mangrove Partners's ten largest holdings make up 55% of its $410M portfolio in Q2 2020.
- Mangrove Partners opened 16 new positions and closed 41 in Q2 2020.
- Mangrove Partners's portfolio value fell 43% quarter-over-quarter to $410M.
Based on Mangrove Partners's 13F filing for Q2 2020, filed 14 Aug 2020.